Children’s Hospital Los Angeles has expanded its cell and gene therapy program to include 12 FDA-approved therapies.
The program now offers more cell and gene therapies than any pediatric center on the West Coast, according to a March 5 news release from the hospital.
The therapies treat neuromuscular disorders, blood disorders, cancer, inherited retinal disease, dermatologic and transplantation-associated conditions.
The hospital plans to launch a clinical trial to study a sickle cell gene therapy product, as well as a CAR T-cell therapy developed by investigators at Children’s Hospital Los Angeles for pediatric solid tumors, the release said.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
